Vaginal Symptoms in Menopause and Barriers to Treatment

undefined
The Vulva and Vagina in
Menopause
 
TAMI SERENE ROWEN MD MS
ASSOCIATE PROFESSOR
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
OBSTETRICS, GYNECOLOGY AND REPRODUCTIVE SCIENCES
How Many Symptoms are we Talking
About
 
Signs and symptoms of GSM
Urinary
Frequency
Urgency
Post-void pain
Dysuria (pain with urination)
Nocturia (urinating at night)
Hematuria (blood in urine)
Recurrent urinary tract infections
Prominence of urethral meatus
Genital
Dryness
Imitation/Burning/Itching of vulva and vagina
Bothersome discharge
Erythema
Tissue fragility/fissures/petechiae
Decreased vaginal moisture/elasticity
Labial shrinkage/labial fusion
Loss of vaginal rugae (folds)
Clitoral hood retraction
Vaginal stenosis and shortening
Sexual
Decreased lubrication with sexual activity
Dyspareunia
Post-coital bleeding
Decreased arousal/orgasm/desire
Hypertonic pelvic floor
Pelvic pain
Vaginal Symptoms and Menopause
Genitourinary Syndrome of Menopause (GSM) previously known as
vulvovaginal atrophy are present in upwards of 905 of women (ranges 39-90%
in various studies)
Women in the United States have a higher rate of discomfort  discussing with a
provider
The symptoms associated with GSM can occur during any reproductive stage.
 Relative low estrogen states can occur in pre-menopausal women, altering
circulating hormonal levels and microbiota.
Fewer than 10% of women with GSM symptoms use prescribed therapy
; this
disparity between prevalence and treatment can be attributed to a lack of
patient and provider education and a failure to recognize symptoms.
Barriers to Treatment
Patient comfort discussing symptoms
Provider comfort asking about symptoms
Limited knowledge about treatment options
Concerns regarding safety of treatments
Classification of treatments as “lifestyle medications”
Cost barriers to treatment
More on Sex: Its not just GSM!
 
 
 
Prevalence of sexual problems associated with sexually related personal distress by 10-year age bands.
Filled circle
, desire; 
open triangle
, arousal; 
filled square
, orgasm; 
open diamond
, any.
From Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. 
Obstet
Gynecol
. 2008;112(5):970-97
Limitations of Current Treatments
For sexual desire FDA approved meds are ONLY for premenopausal
women
Approval for postmenopausal women involves treating psychotropic same as
hormone therapies
Many women seek off label medications, especially Testosterone, which is
not approved for women but has significant evidence for use
The lack of an approved product leads many to seek care with people
who do not follow any known guidelines on prescriptions and expose
patients to harm
Recommendations
Consider importance of approval of variety of FDA approved medications
for GSM
Local vaginal hormones, including estradiol and prasterone
Medications that can be taken orally
Ideal for patients with severe trauma and or pain
Coverage for perimenopausal women to access FDA approved
medications for low desire
Regulation and  oversight for off label use of hormones, focusing on role of
professional guidelines for off label use
Slide Note
Embed
Share

The article discusses the various symptoms associated with the Genitourinary Syndrome of Menopause (GSM) such as decreased vaginal moisture, urinary frequency, and sexual difficulties. It highlights the prevalence of these symptoms in women and the barriers to seeking treatment, including discomfort discussing symptoms, limited knowledge of treatment options, and cost hurdles. The importance of addressing these symptoms and enhancing patient-provider communication is emphasized to improve the quality of life for menopausal women.

  • Menopause Symptoms
  • Genitourinary Syndrome
  • Womens Health
  • Treatment Barriers
  • Patient-Provider Communication

Uploaded on Oct 04, 2024 | 1 Views


Download Presentation

Please find below an Image/Link to download the presentation.

The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.

E N D

Presentation Transcript


  1. The Vulva and Vagina in Menopause TAMI SERENE ROWEN MD MS ASSOCIATE PROFESSOR UNIVERSITY OF CALIFORNIA, SAN FRANCISCO OBSTETRICS, GYNECOLOGY AND REPRODUCTIVE SCIENCES

  2. How Many Symptoms are we Talking About Erythema Tissue fragility/fissures/petechiae Decreased vaginal moisture/elasticity Labial shrinkage/labial fusion Loss of vaginal rugae (folds) Clitoral hood retraction Vaginal stenosis and shortening Signs and symptoms of GSM Urinary Frequency Urgency Post-void pain Dysuria (pain with urination) Nocturia (urinating at night) Hematuria (blood in urine) Recurrent urinary tract infections Prominence of urethral meatus Sexual Decreased lubrication with sexual activity Dyspareunia Post-coital bleeding Decreased arousal/orgasm/desire Hypertonic pelvic floor Pelvic pain Genital Dryness Imitation/Burning/Itching of vulva and vagina Bothersome discharge

  3. Vaginal Symptoms and Menopause Genitourinary Syndrome of Menopause (GSM) previously known as vulvovaginal atrophy are present in upwards of 905 of women (ranges 39-90% in various studies) Women in the United States have a higher rate of discomfort discussing with a provider The symptoms associated with GSM can occur during any reproductive stage. Relative low estrogen states can occur in pre-menopausal women, altering circulating hormonal levels and microbiota. Fewer than 10% of women with GSM symptoms use prescribed therapy; this disparity between prevalence and treatment can be attributed to a lack of patient and provider education and a failure to recognize symptoms.

  4. Barriers to Treatment Patient comfort discussing symptoms Provider comfort asking about symptoms Limited knowledge about treatment options Concerns regarding safety of treatments Classification of treatments as lifestyle medications Cost barriers to treatment

  5. More on Sex: Its not just GSM! Prevalence of sexual problems associated with sexually related personal distress by 10-year age bands. Filled circle, desire; open triangle, arousal; filled square, orgasm; open diamond, any. From Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970-97

  6. Limitations of Current Treatments For sexual desire FDA approved meds are ONLY for premenopausal women Approval for postmenopausal women involves treating psychotropic same as hormone therapies Many women seek off label medications, especially Testosterone, which is not approved for women but has significant evidence for use The lack of an approved product leads many to seek care with people who do not follow any known guidelines on prescriptions and expose patients to harm

  7. Recommendations Consider importance of approval of variety of FDA approved medications for GSM Local vaginal hormones, including estradiol and prasterone Medications that can be taken orally Ideal for patients with severe trauma and or pain Coverage for perimenopausal women to access FDA approved medications for low desire Regulation and oversight for off label use of hormones, focusing on role of professional guidelines for off label use

More Related Content

giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#